These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. New approaches in the treatment of non-small cell lung cancer: taxanes in the treatment of NSCLC: pathways to progress. Kris MG; Tonato M Lung Cancer; 2002 Dec; 38 Suppl 4():1-3. PubMed ID: 12480188 [No Abstract] [Full Text] [Related]
65. Effect of vinorelbine monotherapy in taxane-treated patients with advanced non-small-cell lung cancer. Miyata J; Sano T; Bando H Med Oncol; 2002; 19(1):11-4. PubMed ID: 12025886 [TBL] [Abstract][Full Text] [Related]
66. New platinum derivatives in advanced non-small cell lung cancer. Crinò L; Cappuzzo F Suppl Tumori; 2002; 1(4):S24-5. PubMed ID: 12415810 [No Abstract] [Full Text] [Related]
67. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. Leong SS; Toh CK; Lim WT; Lin X; Tan SB; Poon D; Tay MH; Foo KF; Ho J; Tan EH J Thorac Oncol; 2007 Mar; 2(3):230-6. PubMed ID: 17410046 [TBL] [Abstract][Full Text] [Related]
68. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J Gynecol Oncol; 2004 Jun; 93(3):699-701. PubMed ID: 15196867 [TBL] [Abstract][Full Text] [Related]
74. Chemoresistance in non-small cell lung cancer. Sève P; Dumontet C Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):73-88. PubMed ID: 15720263 [TBL] [Abstract][Full Text] [Related]
75. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Rajkumar SV; Adjei AA Cancer Treat Rev; 1998 Feb; 24(1):35-53. PubMed ID: 9606367 [No Abstract] [Full Text] [Related]
76. Recent development of anti-cancer drugs for treatment of GI malignancies in Japan. Taguchi T Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():76-80. PubMed ID: 11890118 [No Abstract] [Full Text] [Related]
77. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971 [TBL] [Abstract][Full Text] [Related]
78. [Second-line and beyond: Docetaxel in the treatment of non-small-cell lung cancer]. Rinaldi M Tumori; 2001; 87(6):A6-9. PubMed ID: 11995708 [No Abstract] [Full Text] [Related]
79. Vinca alkaloids in the treatment of non-small cell lung cancer. Sørensen JB; Osterlind K; Hansen HH Cancer Treat Rev; 1987 Mar; 14(1):29-51. PubMed ID: 3036349 [No Abstract] [Full Text] [Related]
80. A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum. Bengtson EM; Rigas JR Semin Oncol; 1999 Oct; 26(5 Suppl 16):1-6. PubMed ID: 10585002 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]